No Good News For Pharma In Korea As Most Companies See Sales Decline
This article was originally published in PharmAsia News
Executive Summary
Foreign and domestic companies performed poorly during the first nine months in South Korea with no positive factors on the horizon.
You may also be interested in...
Pfizer's Viagra Challenged As Korea's JW Choongwae Launches ED Product In Korea
SEOUL - South Korea's JW Choongwae Pharmaceutical Corp. launched its new erectile dysfunction product Zepeed (avanafil) in Korea Oct. 19, ahead of approval in the U.S
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Dupixent Shines At ATS, But Experts Question Which Novel Biologic Physicians Will Choose
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.